Adamis Pharmaceuticals Corp. has received US Food and Drug Administration approval for its Zimhi 5mg/0.5ml naloxone hydrochloride for intramuscular or subcutaneous injection indicated for the treatment of opioid overdose.
Zimhi’s approval comes through the 505(b)(2) hybrid pathway, after Adamis previously received two complete response letters related to